Bifunctional Nanoparticles Show Potential in Cancer Models
|
By LabMedica International staff writers Posted on 19 Jun 2017 |

Image: A photomicrograph showing T-cells (red) and tumor cells (green) incubated with control particles (left) or immunoswitch particles (right). The T-cells that have attached to tumor cells are indicated by green arrows (Photo courtesy of Alyssa Kosmides, Johns Hopkins University).
To be successful, an immunotherapeutic approach for treating cancer must overcome the immunosuppressive effects of the tumor microenvironment; a novel bifunctional nanoparticle does just that.
To counteract the immunosuppressive tumor microenvironment, investigators at Johns Hopkins University (Baltimore, MD, USA) coated 100 nanometers in diameter paramagnetic iron particles with two different kinds of antibodies. The pair of antibodies was crafted to block simultaneously the inhibitory checkpoint PD-L1 (programmed death ligand 1) signal while stimulating T-cells via the 4-1BB co-stimulatory pathway. The investigators coined the term "immunoswitch" to describe these novel bifunctional particles.
The investigators tested immunoswitch therapy in several mouse melanoma and colon cancer models. They reported in the June 7, 2017, online edition of the journal ACS Nano that this treatment significantly delayed tumor growth and extended survival in multiple mouse cancer models in comparison to the use of soluble antibodies or nanoparticles separately conjugated with the inhibitory and stimulating antibodies. The immunoswitch-treated mice developed tumors that were nearly 75% smaller than those in animals that received no treatment, whereas soluble antibody only reduced tumor growth by approximately 25%. Half of immunoswitch-treated mice survived after 30 days, whereas all untreated mice died by day 22.
Immunoswitch particles enhanced effector-target cell conjugation and bypassed the requirement for previous knowledge of tumor antigens. Furthermore, the use of the immunoswitch nanoparticles resulted in an increased density, specificity, and in vivo functionality of tumor-infiltrating CD8+ T-cells.
"Immunotherapies have significant potential and yet room for improvement," said senior author Dr. Jonathan P. Schneck, professor of pathology at Johns Hopkins University. "The improvement here was to make, for the first time, a nanoparticle that can interact simultaneously with multiple types of cells in the complex tumor microenvironment, dramatically increasing its effectiveness. The double-duty immunoswitch particles were clearly more effective than a mixture of nanoparticles that each targeted just one protein and acted in a synergistic fashion, but we do not yet know why. It may be that the immunoswitch particles' success comes from bringing T-cells and their targeted tumor cells into close proximity."
Related Links:
Johns Hopkins University
To counteract the immunosuppressive tumor microenvironment, investigators at Johns Hopkins University (Baltimore, MD, USA) coated 100 nanometers in diameter paramagnetic iron particles with two different kinds of antibodies. The pair of antibodies was crafted to block simultaneously the inhibitory checkpoint PD-L1 (programmed death ligand 1) signal while stimulating T-cells via the 4-1BB co-stimulatory pathway. The investigators coined the term "immunoswitch" to describe these novel bifunctional particles.
The investigators tested immunoswitch therapy in several mouse melanoma and colon cancer models. They reported in the June 7, 2017, online edition of the journal ACS Nano that this treatment significantly delayed tumor growth and extended survival in multiple mouse cancer models in comparison to the use of soluble antibodies or nanoparticles separately conjugated with the inhibitory and stimulating antibodies. The immunoswitch-treated mice developed tumors that were nearly 75% smaller than those in animals that received no treatment, whereas soluble antibody only reduced tumor growth by approximately 25%. Half of immunoswitch-treated mice survived after 30 days, whereas all untreated mice died by day 22.
Immunoswitch particles enhanced effector-target cell conjugation and bypassed the requirement for previous knowledge of tumor antigens. Furthermore, the use of the immunoswitch nanoparticles resulted in an increased density, specificity, and in vivo functionality of tumor-infiltrating CD8+ T-cells.
"Immunotherapies have significant potential and yet room for improvement," said senior author Dr. Jonathan P. Schneck, professor of pathology at Johns Hopkins University. "The improvement here was to make, for the first time, a nanoparticle that can interact simultaneously with multiple types of cells in the complex tumor microenvironment, dramatically increasing its effectiveness. The double-duty immunoswitch particles were clearly more effective than a mixture of nanoparticles that each targeted just one protein and acted in a synergistic fashion, but we do not yet know why. It may be that the immunoswitch particles' success comes from bringing T-cells and their targeted tumor cells into close proximity."
Related Links:
Johns Hopkins University
Latest BioResearch News
- BRCA2 Variant Analysis Offers Insights Into Breast Cancer Risk and Treatment
- Statistical Model Helps Track T Cell Behavior During Cancer Immunotherapy
- Blood NAD Levels May Offer Clues to Cardiovascular Health
- Organ-on-Chip System Offers Insights Into Tumor Interactions and Treatment Response
- Multiplexed Single-Cell DNA Methylation Workflow Enables Analysis of Blood Disorders
- Extracellular Vesicle Biomarkers Reveal Shared Signals in Aging and Cancer
- Study Reveals Regulatory DNA Element Involved in Breast Cancer Growth Suppression
- New ddPCR Assays Broaden Options for Multiplex Cancer Mutation Research
- Platelet Biomarkers Identify Progression Signals in Parkinson's Disease
- Molecular Atlas Offers New Framework for Breast Cancer Risk and Treatment Research
- New Method Isolates Neuron-Linked Vesicles From Blood and Cerebrospinal Fluid
- Lung Tumor RNA Variants Offer Clues to Immunotherapy Benefit
- Population-Scale Genome Survey Supports Interpretation of Genetic Testing
- Single-Cell Profiling Reveals Chemotherapy Resistance Signals in Ovarian Cancer
- Genomic Tool Supports Analysis of Repeat Expansions Linked to Inherited Disorders
- CSF Biomarker Meprin-Beta Increases in Alzheimer’s Disease
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







